Kornimate/medical-research-clean huggingface dataset:
non-interventional study on the monthly administration of 300 mg alirocumab (praluent®) with the 2 ml sydney auto-injector

Conditions: Primary Hypercholesterolaemia and Mixed Dyslipidaemia; Atherosclerotic Cardiovascular Disease

Summary: primary objectives: * to assess the effectiveness of the praluent® 2 ml sydney auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment * to assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the praluent® 2 ml sydney auto-injector secondary objective: safety and tolerability

study duration per participant is approximately 12 weeks

Eligibility criteria:
inclusion criteria: * primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia and confirmed vascular disease(\*) and other regular risk factors(\*\*), or confirmed familial heterozygous hypercholesterolaemia * documented maximum dietary and drug lipid-lowering therapy within the last 12 months * inadequate reduction of low-density lipoprotein cholesterol (ldl-c) despite maximum possible dietary and lipid-lowering therapy * the decision of the treating physician to use the praluent® 2 ml sydney auto-injector regardless of study enrolment * no previous therapy with a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor or prior treatment with a pcsk9 inhibitor every 2 weeks (q2w) or monthly (q4w) * signed informed consent form (\*) coronary heart disease (chd), cerebrovascular manifestation, peripheral arterial occlusive disease (paod) (\*\*) for cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (gfr) \< 60 ml/min) exclusion criteria: * planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the observational study * existing treatment by lipid apheresis * age \< 18 years * contraindications to treatment with alirocumab (praluent®) according to the smpc * current participation in a clinical study the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
evaluation of capsular bag shape changes after plate-haptic intraocular lens implantation by ss-oct

Conditions: Age-related Cataract

Summary: evaluation of capsular bag shape changes after plate-haptic intraocular lens implantation by ss-oct.

eighty patients (80 eyes) with simple age-related cataracts were treated from december 2019 to december 2020 in the wenzhou medical university. investigators specifically included patients who were bodily healthy and underwent a successful implantation of an iol. inclusion criteria for this study were patients who were older than 40 years old, had an axial length of 22-26mm, and could complete 4 follow-up visits.

Eligibility criteria:
inclusion criteria: -patients who were older than 40 years old, had an axial length of 22-26mm, and could complete 4 follow-up visits. exclusion criteria: * people cannot cooperate with the check， corneal opacity, glaucoma, and other eye diseases * any other previous intraocular surgery, and intraoperative complications including anterior or posterior capsulartears * continuous circular capsulorhexis is not centered and mydriasis is less than 7mm.

Keywords: ss-oct capsule bag
visual function abnormalities in strabismus and amblyopia and response to therapy

Conditions: Amblyopia; Strabismus

Summary: amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. treated patients have residual visual function deficits. the purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.

to examine the response of therapy on visual functions in amblyopic and strabismic participants. the following visual functions will be measured prior to treatment. eye movements, contrast sensitivity, grating acuity, visual acuity, vernier acuity, binocular visual functions, reading and visual scanning will be measured. the testing will comprise of one or more of the above paradigms depending on participant's cooperation and understanding as majority of the study participants will be children. the above measurements will be repeated during amblyopia therapy ( which comprises of glasses, patching and/or atropine eye drops) and at the completion of treatment. for participants with strabismus requiring strabismus surgery the measurements will be repeated after strabismus surgery.

Eligibility criteria:
inclusion criteria: * history of amblyopia or presence of amblyogenic risk factors. exclusion criteria: * history of neurologic disorders
the role of lung ultrasound during perioperative evaluation

Conditions: Lung Diseases

Summary: accurate pre-operative lung assessment is important to decide the most appropriate anesthesia plan. until now, chest x-ray is considered the standard of care for lung assessment during perioperative evaluation. however, lung ultrasound is a rapid, simple, non-invasive, radiation-free imaging modality and can be used as an alternative to chest radiography for the diagnosis and follow-up of various lung diseases. moreover, the decreased radiation exposure represents a considerable improvement in patient safety. consequently, we decided to compare the data obtained from the lung ultrasound and the chest x-ray.


Eligibility criteria:
inclusion criteria: * adult patients undergoing elective general surgery; * age \>18 years; * ability to provide written consent; * use of chest radiography during the preoperative evaluation. exclusion criteria: * age \< than 18 year; * pregnant patients; * not use of chest radiography during the preoperative evaluation.
characterize the regional distribution of [11c] abp688 in brain by positron emission tomography (pet)

Conditions: Depression

Summary: this study is designed to characterize the regional distribution of \[11c\] abp688 in brain by positron emission tomography (pet).


Eligibility criteria:
inclusion criteria: * male and female subjects 55-80 (inclusive) * subjects in good health at screening: * oral body temperature between 35-37.5c * systolic blood pressure: 90-140 mm hg * diastolic blood pressure: 50-90 mm hg * pulse rate: 40-90 bpm * female subjects of child bearing potential must have been using a double-barrier local contraception * postmenopausal women must have had no menstrual bleeding * subjects must have weighed at least 50 kg * all subjects must provide informed consent * all subjects must have been able to communicate well with investigator specific to major depression disorder (mdd) patients had to show following level of symptomatology: * ham-d (17-item scale) \> 16 * cgi \> 4 (moderately ill) exclusion criteria: specific criteria for healthy volunteers: - presence and/or history of clinically significant major neurological or psychiatric disorder specific criteria for mdd patients: * presence and/or history of a clinically significant major neurological or psychiatric disorder other than mdd or generalized anxiety disorder * axis i co-morbidity was excluded except anxiety spectrum disorders criteria for both: * smokers * pregnancy * subjects with history of or symptoms/complaints consistent with mild cognitive impairment * use of any psychotropic prescription drugs * coffee consumers more than 6 cups/day * participation in any clinical investigation * donation or loss of 400 ml or more of blood * significant illness within 2 weeks prior to dosing * a known hypersensitivity to study drug * mri scan that showed evidence of stroke * any surgical or medical condition which might have significantly altered distribution * clinical evidence of any abnormal lab value * history of immunodeficiency disease * positive hepatitis b surface antigen * presence of contraindications to pet scan investigations- presence of contraindications to mri investigations * evidence from an allen test of incomplete communication * history of drug or alcohol abuse * current use of anticonvulsant * significant radiation exposure other protocol-defined inclusion/exclusion criteria may apply.

Keywords: abp688 tracer depression
evaluation of the effect of minimally invasive procedures used in management of salivary ductal pathologies on patients' symptomatology and gland function

Conditions: Salivary Gland Stone; Salivary Gland Diseases

Summary: aim of the current study was to evaluate the minimally invasive techniques in the management of salivary gland ductal pathologies


Eligibility criteria:
inclusion criteria: * all patients manifesting with either submandibular or parotid salivary gland ductal pathologies including: * sialolithiasis (salivary stones). * salivary ductal stenosis or stricture. * children with juvenile recurrent parotitis. * sjogren's syndrome. * radio-iodine induced sialadenitis. exclusion criteria: * patients who are unfit for surgery. * patients with previous submandibular or parotid surgical resection. * patients with salivary tumors either benign or malignant.
feasibility and acceptability of music therapy for chronic pain

Conditions: Chronic Pain

Summary: the purpose of the study is to examine the feasibility and acceptability of two music interventions delivered through telehealth for chronic musculoskeletal pain. this pilot study evaluates outcomes (feasibility, acceptability, pain and associated outcomes) in a single-component, minimally interactive music listening (ml) intervention and a multi-component, more interactive music imagery (mi) intervention.

familia is a 3-arm, parallel group, pilot trial. sixty veterans will be randomized to one of three conditions: mi, ml, or usual care. aim 1 is to test the feasibility and acceptability of a multi-component, interactive mi intervention (8-weekly, individual sessions) and a single-component, minimally interactive ml intervention (independent music listening). feasibility metrics related to recruitment, retention, engagement, and completion of treatment protocol and questionnaires will be assessed. up to 20 qualitative interviews will be conducted to assess veteran experiences with both interventions, including perceived benefits, acceptability, barriers, and facilitators. interview transcripts will be coded and analyzed for emergent themes. aim 2 is to explore the effects of mi and ml versus usual care on pain and associated patient-centered outcomes. these outcomes and potential mediators will be explored through changes from baseline to follow-up assessments at 1, 3, and 4 months. descriptive statistics will be used to describe outcomes; this pilot study is not powered to detect differences in outcomes.

Eligibility criteria:
inclusion criteria: * chronic (\> 6 months) musculoskeletal pain of at least moderate severity (≥5 on 0-10 numeric scale) * access to a personal computer, tablet computer, and/or smartphone, * ability to pass technology assessment screen, and * not currently receiving music therapy services exclusion criteria: * serious or unstable medical (e.g., congestive heart failure, chronic obstructive pulmonary disease) or psychiatric illness (e.g., psychosis, mania) or housing insecurity that could compromise study participation, * suicidal ideation with current intent/plan, * hearing or cognitive impairment that may interfere with music listening or abstract thinking needed for imagery work, * lack access to a personal computer, tablet computer, and/or smartphone, * unable to pass technology assessment screen, or * currently receiving music therapy services.
clinical study on the safety and preliminary efficacy of huc-mscs intravenous infusion therapy for ards

Conditions: Acute Respiratory Distress Syndrome

Summary: the object of this study is to observe the safety of umbilical cord mesenchymal stem cell therapy for acute respiratory distress syndrome, consisting with two phases.

the secondary objectives are to observe the preliminary efficacy of umbilical cord mesenchymal stem cell therapy for acute respiratory distress syndrome. phase one is an open-label, dose-escalation clinical study. following safety and tolerability conclusions from phase one, and upon evaluation and approval by the data safety committee and ethics committee, conduct phase two study, which will be a randomized, double-blind, placebo-controlled study. dosage selection will be based on the safest and most effective dosage determined from phase one results.

Eligibility criteria:
inclusion criteria: 1. age greater than 18 years, regardless of gender; 2. meeting the ards berlin diagnostic criteria; 3. definite diagnosis within 72 hours; 4. p/f \< 150mmhg; 5. understanding and signing informed consent. exclusion criteria: 1. women of childbearing potential with a positive serum pregnancy test before medication, pregnant women, or lactating women; 2. ards directly caused by physical or chemical factors; 3. moderate to severe liver damage (child-pugh score \>12); 4. chronic heart failure, new york heart association functional class iv; 5. severe kidney disease undergoing renal replacement therapy; 6. severe lung disease, grade iii or iv pulmonary hypertension, receiving oxygen therapy or ventilator support for more than one month in the six months prior to screening, end-stage lung disease, or severe physical limitations due to chest wall deformity; 7. immunodeficiency, receiving immunosuppressive therapy within 2 weeks (except for low-dose corticosteroids), or with lymphoma, leukemia, or acquired immune deficiency syndrome; history of organ transplantation, bone marrow transplantation, or autologous hematopoietic stem cell suppression; 8. expected survival time of less than 48 hours due to terminal illness; 9. patients diagnosed with deep vein thrombosis (dvt) or pulmonary embolism (pe) in the past three months; 10. patients receiving ecmo therapy; 11. hepatitis b, hepatitis c, syphilis, or hiv infection. 12. egfr \< 30ml/min/bsa; 13. alt \> 5 × uln; 14. absolute neutrophil count \< 1500/μl; 15. subjects who have participated in other clinical studies within the past month (excluding those who have not received intervention), or are currently participating in other experimental treatments; 16. subjects deemed unlikely to benefit from the study by the investigator, or deemed unsuitable for participation in this study.

Keywords: acute respiratry distress syndrome human umbilical cord derived mesenchymal stem cell clinical study
bowel preparation impact on the intestinal microbiome: oral preparation vs enema

Conditions: Colorectal Cancer

Summary: mechanical bowel preparation for left-sided colorectal surgery remains standard in most cases. however, there are some discrepancies on how to prepare the bowl, while rectal enema and oral agents are both available methods. the knowledge of intestinal microbiome role on surgical outcomes is increasing, since few recent reports linked microbiome composition to postoperative complications, such as anastomotic insufficiency. although, it is not clear how the bowel preparation affects the gut microbiome. therefore, different bowel preparation techniques impact on gut microbiome will be studied.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 y.; 2. signed informed consent; 3. left-side colorectal resection for colorectal cancer; exclusion criteria: 1. anticipated ileostoma; 2. allergy to oral preparation agents; 3. multivisceral surgery; 4. emergency surgery; 5. history of inflammatory bowel disease; 6. history of surgery disrupting gastrointestinal tract integrity; 7. signs of tumor obturating the lumen of the bowel; 8. pregnancy;
bronchodilator responsiveness in obliterative bronchiolitis

Conditions: Obliterative Bronchiolitis

Summary: this study has been designed to provide a substantial evidence of acute bronchodilator responsiveness to two sequentially inhaled drugs, a beta2-agonist (i.e., albuterol) and an anticholinergic (i.e., tiotropium bromide), in a group of patients who developed obliterative bronchiolitis after hematopoietic stem cell transplantation.

obliterative bronchiolitis is a life-threatening non-infectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (hsct). it is characterized by the development of an obstructive abnormality which has been considered to be insensitive to bronchodilator treatments. however, this knowledge stems from measurements of forced expiratory volume in 1 s (fev1) which is relatively insensitive to changes in small airway caliber. moreover, it is known from studies in chronic obstructive pulmonary disease that symptoms improve after bronchodilator treatment even when fev1 is minimally increased and correlate with the reduction of lung hyperinflation, which is the major consequence of severe expiratory airflow limitation. therefore, measurements of airway caliber by parameters not affected by volume history and absolute lung volumes are preferable for assessing the effect of bronchodilator interventions. in the current study, the bronchodilators responsiveness will be assessed by using not only spirometry but also measurements of absolute lung volumes and the forced expiratory flow of a partial maneuver (v'part) started from submaximal lung inflation, thus free of volume history effects.

Eligibility criteria:
inclusion criteria: * obliterative bronchiolitis (ob) following allogeneic hsct * fev1 to slow inspiratory vital capacity (vc) ratio (fev1/vc)\<5th percentile * fev1 \ 10% of pre-hsct value * evidence of ob by computed tomography scanning * negative microbiological yields in bronchoalveolar lavage fluid * chronic graft-versus-host disease score \>0 * negative history for bronchial asthma, chronic obstructive pulmonary disease or other significant respiratory disease. exclusion criteria: * inability to perform lung function maneuvers * pre-existent chronic lung disease other than ob

Keywords: obliterative bronchiolitis bronchodilator responsiveness partial forced expiratory flow lung volumes
management of bone metastases

Conditions: Cancer; Bone Metastases

Summary: bone metastases (bm) are responsible for various bone events such as pathological fractures, spinal cord compression, preventive bone surgery, and severe bone pain requiring palliative radiotherapy management. bone-targeted treatments, such as denosumab and bisphosphonates, are approved for preventing bone events caused by bm in patients being treated for metastatic cancer. clinical research on solid tumors has shown a reduction in the incidence of bone events with these treatments. given this demonstrated effectiveness, it is important to optimize patient management by studying the characteristics of treated versus untreated patients, the incidence of bone events, and the impact of these events on patients. a first nationwide study using egb data (1/97th of the population) showed a low rate of management with bone-targeted treatment. only 9% of patients with bm or a bone event associated with a cancer diagnosis received bone-targeted treatment. to validate and refine these results, we aim to replicate the protocol at lyon sud hospital. indeed, a greater amount of information will be available to answer the research question, and a number of biases can be avoided.


Eligibility criteria:
* inclusion criteria \* : -- patients with an icd 10 code for bone metastases: 79.5 * and/or patients having had a skeletal event (pathological fracture; spinal cord compression; malignant hypercalcemia; bone pain and preventive orthopedic surgery or spine surgery) associated with a diagnosis of oncological pathology * adult patients * no opposition * exclusion criteria \* : * - patient hospitalized for a sarcoma during the pre-inclusion period and inclusion * patients with a long-term illiness (lti) associated with a hospital diagnosis of kaposi sarcoma over the same period as lti * patient with a diagnosis of pathological fracture linked to a diagnosis of osteoporosis (m80) * patient under guardianship or curatorship * minor patients * patients not affiliated to the social security system at least 3 years before the diagnosis of mo and during the follow-up period. * patient already diagnosed with known bone metastases in the previous year.

Keywords: bone metastases bone target agent medical care international recommendation
treating post-lyme disease syndrome with acetogenins

Conditions: Post-Lyme Disease Syndrome (PLDS)

Summary: to access the effectiveness of acetogenins in treating post-lyme disease syndrome (plds).

to access the effectiveness of acetogenins in treating post-lyme disease syndrome (plds). after failure of antibiotic therapy to relive persistent symptoms of lyme disease, the use of acetogenins to elevate post-lyme disease syndrome.

Eligibility criteria:
inclusion criteria: 1. a positive western blot for lyme disease that has been treated with antibiotics but the symptoms persist post treatment. 2. must be able to swallow and mixed powder drink. - exclusion criteria: 1. non positive western blot test. 2. positive western blot test where the indivual has not been treated with antibiotics. -
nutritional support in patients with nutritional risk. how we can improved the prognosis and quality of life

Conditions: Malnutrition; Quality of Life

Summary: background: many malnourished hospital patients remain after discharge. we aimed to enhance the meal experience after discharge by delivering meals together with physical support at the home and tested if this increased food intake affected survival and quality of life. patients and methods: 60 discharged patients suffering from nutritional (must\>2) and financial frailty were included. control group (c) took their regular nutrition at home for 6 months and study group (s) received a daily dinner tray sponsored by the municipality. hazalla philanthropic organization encouraged the patients at lunch for 6 months. body composition (quadstat 4000, bodystat, uk), energy requirements (fitmate- cosmed, italy) were measured at recruitement. primary outcome was 180 days survival. in addition, in the recruitment stage and after a period of 3 and 6 months, depression and anxiety questionnaire (hads), quality of life questionnaire-sf36and fim questionnaire - designed to examine the level of independence of patients with disability were performed at days 0, 90 and 180. statistical analysis used t- test and anova repeated measures. the study was approved by local irb.


Eligibility criteria:
inclusion criteria: * must =\>2 * region of living bney-brak or petah-tikwa * fine cognitive state exclusion criteria: * progressive cancer * dementia * fiddling by peg or enteral nutrient via naso gastric tube * psychiatrics disorder